|
1
|
Bao S, Wu Q, McLendon RE, Hao Y, et al:
Glioma stem cells promote radioresistance by preferential
activation of the DNA damage response. Nature. 444:756–760. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mannino M and Chalmers AJ: Radioresistance
of glioma stem cells: intrinsic characteristic or property of the
‘microenvironment-stem cell unit’? Mol Oncol. 5:374–386. 2011.
|
|
3
|
Liu G, Yuan X, Zeng Z, et al: Analysis of
gene expression and chemoresistance of CD133+ cancer
stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang MK and Kang SK: Tumorigenesis of
chemotherapeutic drug-resistant cancer stem-like cells in brain
glioma. Stem Cells Dev. 16:837–847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohyeldin A, Garzón-Muvdi T and
Quiñones-Hinojosa A: Oxygen in stem cell biology: a critical
component of the stem cell niche. Cell Stem Cell. 7:150–161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parmar K, Mauch P, Vergilio JA, et al:
Distribution of hematopoietic stem cells in the bone marrow
according to regional hypoxia. Proc Natl Acad Sci USA.
104:5431–5436. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heddleston JM, Li Z, McLendon RE, et al:
The hypoxic microenvironment maintains glioblastoma stem cells and
promotes reprogramming towards a cancer stem cell phenotype. Cell
Cycle. 8:3274–3284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mao XG, Yan M, Xue XY, et al:
Overexpression of ZNF217 in glioblastoma contributes to the
maintenance of glioma stem cells regulated by hypoxia-inducible
factors. Lab Invest. 91:1068–1078. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soeda A, Park M, Lee D, et al: Hypoxia
promotes expansion of the CD133-positive glioma stem cells through
activation of HIF-1alpha. Oncogene. 28:3949–3959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bar EE, Lin A, Mahairaki V, et al: Hypoxia
increases the expression of stem-cell markers and promotes
clonogenicity in glioblastoma neurospheres. Am J Pathol.
177:1491–1502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kolenda J, Jensen SS, Aaberg-Jessen C, et
al: Effects of hypoxia on expression of a panel of stem cell and
chemoresistance markers in glioblastoma-derived spheroids. J
Neurooncol. 103:43–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iida H, Suzuki M, Goitsuka R, et al:
Hypoxia induces CD133 expression in human lung cancer cells by
up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79.
2012.PubMed/NCBI
|
|
13
|
Mathieu J, Zhang Z, Zhou W, et al: HIF
induces human embryonic stem cell markers in cancer cells. Cancer
Res. 71:4640–4652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Monzani E, Facchetti F, Galmozzi E, et al:
Melanoma contains CD133 and ABCG2 positive cells with enhanced
tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O’Brien CA, Pollett A, Gallinger S, et al:
A human colon cancer cell capable of initiating tumour growth in
immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI
|
|
16
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma S, Chan KW, Hu L, et al: Identification
and characterization of tumorigenic liver cancer stem/progenitor
cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tirino V, Desiderio V, Paino F, et al:
Human primary bone sarcomas contain CD133+ cancer stem
cells displaying high tumorigenicity in vivo. FASEB J.
25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beier D, Hau P, Proescholdt M, et al:
CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show
differential growth characteristics and molecular profiles. Cancer
Res. 67:4010–4015. 2007.
|
|
21
|
Joo KM, Kim SY, Jin X, et al: Clinical and
biological implications of CD133-positive and CD133-negative cells
in glioblastomas. Lab Invest. 88:808–815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ogden AT, Waziri AE, Lochhead RA, et al:
Identification of A2B5+CD133−
tumor-initiating cells in adult human gliomas. Neurosurgery.
62:505–514. 2008.
|
|
23
|
Wang J, Sakariassen P, Tsinkalovsky O, et
al: CD133 negative glioma cells form tumors in nude rats and give
rise to CD133 positive cells. Int J Cancer. 122:761–768. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Platet N, Liu SY, Atifi ME, et al:
Influence of oxygen tension on CD133 phenotype in human glioma cell
cultures. Cancer Lett. 258:286–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Z, Wang Z, Fan Y, et al: Expression
of CD133 in SW620 colorectal cancer cells is modulated by the
microenvironment. Oncol Lett. 4:75–79. 2012.PubMed/NCBI
|
|
26
|
Sutherland RM: Cell and environment
interactions in tumor microregions: the multicell spheroid model.
Science. 240:177–184. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Freyer JP, Tustanoff E, Franko AJ, et al:
In situ oxygen consumption rates of cells in V-79 multicellular
spheroids during growth. J Cell Physiol. 118:53–61. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Freyer JP and Sutherland RM: A reduction
in the in situ rates of oxygen and glucose consumption of cells in
EMT6/Ro spheroids during growth. J Cell Physiol. 124:516–524. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kemper K, Sprick MR, de Bree M, et al: The
AC133 epitope, but not the CD133 protein, is lost upon cancer stem
cell differentiation. Cancer Res. 70:719–729. 2010. View Article : Google Scholar : PubMed/NCBI
|
